Advertisement

Prostate Cancer Imaging with 18F-Fluciclovine

  • Bital Savir-Baruch
    Correspondence
    Corresponding author. Department of Medical Imaging, Division of Nuclear Medicine University of Arizona Banner University Medical Center-Tucson 1501 N. Campbell, Tucson, AZ 85724.
    Affiliations
    Department of Medical Imaging, Division of Nuclear Medicine, University of Arizona, Banner University Medical Center-Tucson, 1501 N. Campbell, Tucson, AZ 85724, USA

    Department of Radiology, Loyola University Chicago Stritch School of Medicine, 2160 S 1st Avenue, Maywood, IL 60153, USA
    Search for articles by this author
  • David M. Schuster
    Affiliations
    Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, Room E152, 1364 Clifton Road, Atlanta, GA 30322, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Axumin (fluciclovine F 18) injection, printed labeling.
        (Available at:)
        • Okudaira H.
        • Shikano N.
        • Nishii R.
        • et al.
        Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer.
        J Nucl Med. 2011; 52: 822-829
        • Oka S.
        • Okudaira H.
        • Yoshida Y.
        • et al.
        Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells.
        Nucl Med Biol. 2012; 39: 109-119
        • Nye J.A.
        • Schuster D.M.
        • Yu W.
        • et al.
        Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans.
        J Nucl Med. 2007; 48: 1017-1020
        • Lovrec P.
        • Schuster D.M.
        • Wagner R.H.
        • et al.
        Characterizing and mitigating bladder radioactivity on (18)F-fluciclovine PET/CT.
        J Nucl Med Technol. 2020; 48: 24-29
        • Turkbey B.
        • Mena E.
        • Shih J.
        • et al.
        Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
        Radiology. 2014; 270: 849-856
        • Schuster D.M.
        • Taleghani P.A.
        • Nieh P.T.
        • et al.
        Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.
        Am J Nucl Med Mol Imaging. 2013; 3: 85-96
        • Elschot M.
        • Selnæs K.M.
        • Sandsmark E.
        • et al.
        A PET/MRI study towards finding the optimal [(18)F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.
        Eur J Nucl Med Mol Imaging. 2017; 44: 695-703
        • Jambor I.
        • Kuisma A.
        • Kahkonen E.
        • et al.
        Prospective evaluation of (18)F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial).
        Eur J Nucl Med Mol Imaging. 2018; 45: 355-364
        • Biscontini G.
        • Romagnolo C.
        • Cottignoli C.
        • et al.
        18F-Fluciclovine positron emission tomography in prostate cancer: a systematic review and diagnostic meta-analysis.
        Diagnostics (Basel, Switzerland). 2021; 11: 304
        • Suzuki H.
        • Jinnouchi S.
        • Kaji Y.
        • et al.
        Diagnostic performance of 18F-fluciclovine PET/CT for regional lymph node metastases in patients with primary prostate cancer: a multicenter phase II clinical trial.
        Jpn J Clin Oncol. 2019; 49: 803-811
        • Selnaes K.M.
        • Kruger-Stokke B.
        • Elschot M.
        • et al.
        (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
        Eur Radiol. 2018; 28: 3151-3159
        • Alemozaffar M.
        • Akintayo A.A.
        • Abiodun-Ojo O.A.
        • et al.
        [(18)F]Fluciclovine positron emission tomography/computerized tomography for preoperative staging in patients with intermediate to high risk primary prostate cancer.
        J Urol. 2020; 204: 734-740
        • Hoekstra R.J.
        • Beulens A.
        • Vrijhof E.
        • et al.
        Diagnostic accuracy of 18F-fluciclovine PET/CT in primary lymph node staging of prostate cancer.
        Nucl Med Commun. 2021; 42: 476-481
        • Zanoni L.
        • Bianchi L.
        • Nanni C.
        • et al.
        [(18)F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial.
        Eur J Nucl Med Mol Imaging. 2021; 49: 390-409
        • Schuster D.
        • Votaw J.
        • Nieh P.
        • et al.
        Initial experience with the radiotracer anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
        J Nucl Med. 2007; 48: 56-63
        • Schuster D.M.
        • Nieh P.T.
        • Jani A.B.
        • et al.
        Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
        J Urol. 2014; 191: 1446-1453
        • Odewole O.A.
        • Tade F.I.
        • Nieh P.T.
        • et al.
        Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT.
        Eur J Nucl Med Mol Imaging. 2016; 43: 1773-1783
        • Andriole G.L.
        • Kostakoglu L.
        • Chau A.
        • et al.
        The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial.
        J Urol. 2019; 201: 322-331
        • Abiodun-Ojo O.A.
        • Jani A.B.
        • Akintayo A.A.
        • et al.
        Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on (18)F-fluciclovine PET/CT guidance.
        J Nucl Med. 2021; 62: 1089-1096
        • Chen B.
        • Wei P.
        • Macapinlac H.A.
        • et al.
        Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.
        Nucl Med Commun. 2019; 40: 940-946
        • Kim S.J.
        • Lee S.W.
        The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis.
        Clin Radiol. 2019; 74: 886-892
        • Bach-Gansmo T.
        • Nanni C.
        • Nieh P.T.
        • et al.
        Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer.
        J Urol. 2017; 197: 676-683
        • Abiodun-Ojo O.A.
        • Akintayo A.A.
        • Akin-Akintayo O.O.
        • et al.
        (18)F-fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.
        J Nucl Med. 2019; 60: 1531-1536
        • Salavati A.
        • Gencturk M.
        • Koksel Y.
        • et al.
        A bicentric retrospective analysis of clinical utility of (18)F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?.
        Eur J Nucl Med Mol Imaging. 2021; 48: 4463-4471
        • Jani A.B.
        • Schreibmann E.
        • Goyal S.
        • et al.
        18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
        Lancet. 2021; 397: 1895-1904
        • Savir-Baruch B.
        • Lovrec P.
        • Solanki A.A.
        • et al.
        Fluorine-18-Labeled fluciclovine PET/CT in clinical practice: factors affecting the rate of detection of recurrent prostate cancer.
        AJR Am J Roentgenol. 2019; 213: 851-858
        • Nakamoto R.
        • Harrison C.
        • Song H.
        • et al.
        The clinical utility of (18)F-fluciclovine PET/CT in biochemically recurrent prostate cancer: an academic center experience post FDA approval.
        Mol Imaging Biol. 2021; 23: 614-623
        • Bulbul J.E.
        • Grybowski D.
        • Lovrec P.
        • et al.
        Positivity rate of [(18)F]fluciclovine PET/CT in patients with suspected prostate cancer recurrence at PSA levels below 1 ng/mL.
        Mol Imaging Biol : MIB : official Publ Acad Mol Imaging. 2022; 24: 42-49
        • Marcus C.
        • Abiodun-Ojo O.A.
        • Jani A.B.
        • et al.
        Clinical utility of (18)F-Fluciclovine PET/CT in recurrent prostate cancer with very low (≤0.3 ng/mL) prostate-specific antigen levels.
        Am J Nucl Med Mol Imaging. 2021; 11: 406-414
      2. Bulbul J.E., Hashem A., Grybowski D., et al., Effect of hormonal therapy on 18F-fluciclovine PET/CT in thedetection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen, Urol Oncol, 40 (8), 2022, 379.e9-379.e16.

        • Savir-Baruch B.
        • Choyke P.L.
        • Rowe S.P.
        • et al.
        Role of (18)F-fluciclovine and prostate-specific membrane antigen PET/CT in guiding management of oligometastatic prostate cancer: AJR expert panel narrative review.
        AJR Am J Roentgenol. 2021; 216: 851-859
        • Kim E.H.
        • Siegel B.A.
        • Teoh E.J.
        • et al.
        Prostate cancer recurrence in patients with negative or equivocal conventional imaging: a role for (18)F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.
        Urol Oncol. 2021; 39: 365-369
        • Savir-Baruch B.
        • Banks K.P.
        • McConathy J.E.
        • et al.
        ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer.
        Clin Nucl Med. 2018; 43: 909-917
        • Tade F.I.
        • Sajdak R.A.
        • Gabriel M.
        • et al.
        Best practices for (18)F-fluciclovine PET/CT imaging of recurrent prostate cancer: a guide for technologists.
        J Nucl Med Technol. 2019; 47: 282-287
        • Nanni C.
        • Zanoni L.
        • Bach-Gansmo T.
        • et al.
        [(18)F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.
        Eur J Nucl Med Mol Imaging. 2020; 47: 579-591
        • Gill H.S.
        • Tade F.
        • Greenwald D.T.
        • et al.
        Metastatic male breast cancer with increased uptake on 18F-fluciclovine PET/CT scan.
        Clin Nucl Med. 2018; 43: 23-24
        • Schuster D.M.
        • Nanni C.
        • Fanti S.
        • et al.
        Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.
        J Nucl Med : official Publ Soc Nucl Med. 2014; 55: 1986-1992
        • Bitar R.
        • Martiniova L.
        • Bell D.
        • et al.
        Incidental 18F-Fluciclovine uptake in a warthin tumor of the parotid gland in a patient undergoing PET/CT imaging for biochemical recurrent prostate cancer.
        Clin Nucl Med. 2020; 45: e208-e210
        • Raghavan K.
        • Flavell R.R.
        • Westphalen A.C.
        • et al.
        Gastrointestinal stromal tumor incidentally detected on 18F-Fluciclovine PET/CT.
        Clin Nucl Med. 2021; 46: 345-347
        • Parihar A.S.
        • Schmidt L.R.
        • Dehdashti F.
        • et al.
        Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
        J Nucl Med. 2021; 63: 713-719
        • Hoyle J.M.
        • Lenzie A.
        • Galgano S.J.
        • et al.
        Synchronous malignancies identified by (18)F-fluciclovine positron emission tomography for prostate cancer: case series and mini-review.
        Clin Genitourin Cancer. 2021; 19: e37-e40
        • Elschot M.
        • Selnaes K.M.
        • Sandsmark E.
        • et al.
        Combined (18)F-fluciclovine PET/MRI shows potential for detection and characterization of high-risk prostate cancer.
        J Nucl Med : official Publ Soc Nucl Med. 2018; 59: 762-768
        • Galgano S.J.
        • McDonald A.M.
        • Rais-Bahrami S.
        • et al.
        Utility of (18)F-fluciclovine PET/MRI for staging newly diagnosed high-risk prostate cancer and evaluating response to initial androgen deprivation therapy: a prospective single-arm pilot study.
        AJR Am J Roentgenol. 2021; 217: 720-729
        • Selnæs K.M.
        • Krüger-Stokke B.
        • Elschot M.
        • et al.
        Detection of recurrent prostate cancer with 18F-fluciclovine PET/MRI.
        Front Oncol. 2020; 10
        • Chen B.
        • Bathala T.K.
        • Xu G.
        • et al.
        Comparison of diagnostic utility of fluciclovine PET/CT versus pelvic multiparametric MRI for prostate cancer in the pelvis in the setting of rising PSA after initial treatment.
        Clin Nucl Med. 2020; 45: 349-355
      3. PYLARIFY® (piflufolastat F 18) injection, for intravenous use Initial U.S. Approval: 2021.
        (Available at:)
      4. Illuccix FDA approval press release.
        (Available at:)
      5. Ga PSMA-11 UCLA/UCSF.
        (Available at:)
      6. NCCN prostate 2.
        (Available at:)
        • Calais J.
        • Ceci F.
        • Eiber M.
        • et al.
        18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
        Lancet Oncol. 2019; 20: 1286-1294
        • Pernthaler B.
        • Kulnik R.
        • Gstettner C.
        • et al.
        A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT.
        Clin Nucl Med. 2019; 44: e566-e573
      7. Abiodun-Ojo O, Jani A, Adediran O, et al. 18F-Fluciclovine PET/CT and 68Ga-PSMA PET/CT guidance of salvage radiotherapy in patients with biochemical recurrence postprostatectomy: interim analysis of a secondary endpoint from a randomized trial. Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting. Chicago, Illinois; 2021. RSNA meeting was in Nov 28, 2021 – Dec 2, 2021.